Skip to main content

Cognitive Impairment

4
Pipeline Programs
14
Companies
15
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

13 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
ExelonPhase 41 trial
Active Trials
NCT00669344Completed50Est. Feb 2008
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
2g Centella asiatica water extract productPhase 11 trial
Active Trials
NCT03937908Terminated5Est. Dec 2020
Cognition Therapeutics
Cognition TherapeuticsPA - Pittsburgh
1 program
1
CT1812Phase 11 trial
Active Trials
NCT02570997Completed80
Theranexus
TheranexusFrance - Lyon
1 program
1
THN 201Phase 11 trial
Active Trials
NCT03698695Completed152Est. Dec 2019
Innovation Pharmaceuticals
2 programs
Dual-task GroupN/A1 trial
Structured ICT-assisted multimodal lifestyle interventionN/A1 trial
Active Trials
NCT05384639Unknown30Est. Jul 2022
NCT05565170Active Not Recruiting156Est. Mar 2025
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
GnRHant + E2N/A1 trial
Leuprolide acetateN/A1 trial
Active Trials
NCT03112226Completed19Est. Jun 2020
NCT02122198Completed17Est. Sep 2017
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1. cognitive stimulationN/A1 trial
Active Trials
NCT06662474Not Yet RecruitingEst. Dec 2026
Alliance Pharmaceuticals
1 program
Cognitive AssessmentN/A1 trial
Active Trials
NCT03382444Completed19Est. Sep 2019
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Control PhaseN/A1 trial
Active Trials
NCT06528951Active Not Recruiting69Est. Sep 2024
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
Meditative MovementN/A1 trial
Active Trials
NCT04213872Completed27Est. Sep 2020
Lumos Pharma
Lumos PharmaTX - Austin
1 program
TMS and Lumosity®cognitive retrainingN/A1 trial
Active Trials
NCT03701932Completed11Est. Jul 2019
Avenue Therapeutics
Avenue TherapeuticsFL - Bay Harbor Islands
1 program
cognitive assessmentN/A1 trial
Active Trials
NCT05484960Unknown73Est. Dec 2024
Eisai
EisaiChina - Liaoning
1 program
AriceptPHASE_21 trial
Active Trials
NCT00103948Completed165Est. Feb 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozExelon
EisaiAricept
Oregon Therapeutics2g Centella asiatica water extract product
TheranexusTHN 201
Cognition TherapeuticsCT1812
T-Therapeutics1. cognitive stimulation
Human BioSciencesControl Phase
Innovation PharmaceuticalsStructured ICT-assisted multimodal lifestyle intervention
Avenue Therapeuticscognitive assessment
Innovation PharmaceuticalsDual-task Group
Alliance PharmaceuticalsCognitive Assessment
Colorado TherapeuticsGnRHant + E2
Angeles TherapeuticsMeditative Movement
Lumos PharmaTMS and Lumosity®cognitive retraining
Colorado TherapeuticsLeuprolide acetate

Clinical Trials (15)

Total enrollment: 873 patients across 15 trials

RIVastigmine In Vascular cognitivE Impairment

Start: Feb 2006Est. completion: Feb 200850 patients
Phase 4Completed

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Start: Feb 2005Est. completion: Feb 2007165 patients
Phase 2Completed
NCT03937908Oregon Therapeutics2g Centella asiatica water extract product

Pharmacokinetics Centella Asiatica Product (CAP) in Mild Cognitive Impairment

Start: Oct 2019Est. completion: Dec 20205 patients
Phase 1Terminated

A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers

Start: Sep 2018Est. completion: Dec 2019152 patients
Phase 1Completed

Ascending Dose Study of CT1812 in Healthy Volunteers

Start: Sep 201580 patients
Phase 1Completed
NCT06662474T-Therapeutics1. cognitive stimulation

Cognitive Impairment in Treated Breast Cancer Survivors: Possible Approaches

Start: Nov 2024Est. completion: Dec 2026
N/ANot Yet Recruiting

Impact of Resistance Training Volume on Cognitive Function and Physical Performance in Cognitively Impaired Individuals

Start: Oct 2023Est. completion: Sep 202469 patients
N/AActive Not Recruiting
NCT05565170Innovation PharmaceuticalsStructured ICT-assisted multimodal lifestyle intervention

Digitally Supported Lifestyle Programme to Promote Brain Health Among Older Adults

Start: Jan 2023Est. completion: Mar 2025156 patients
N/AActive Not Recruiting
NCT05484960Avenue Therapeuticscognitive assessment

The Philippine Neurological Association One Database -Dementia

Start: Dec 2021Est. completion: Dec 202473 patients
N/AUnknown

Dual-task Cycling System on Cognitive Function for the Elderly

Start: Jan 2021Est. completion: Jul 202230 patients
N/AUnknown

The Kidney and The Brain Study - Assessment of Cognitive Impairment in Advanced CKD

Start: Feb 2018Est. completion: Sep 201919 patients
N/ACompleted

Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function

Start: Feb 2018Est. completion: Jun 202019 patients
N/ACompleted

Gene Expression, Meditative Movement, and Emotional Distress (GME)

Start: Jul 2017Est. completion: Sep 202027 patients
N/ACompleted
NCT03701932Lumos PharmaTMS and Lumosity®cognitive retraining

Mental Activity During (TMS) Therapy for Depression

Start: Mar 2015Est. completion: Jul 201911 patients
N/ACompleted

Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women

Start: Sep 2014Est. completion: Sep 201717 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.